Prostate-specific membrane antigen (PSMA)-PET/CT imaging identified metastatic prostate cancer in almost half of high-risk cases missed by conventional imaging, a retrospective analysis showed.

Research presented at the American Society of Clinical Oncology Annual Meeting found prostate-specific membrane antigen ligand positron emission tomography (PSMA-PET) to be associated with worse ...

PSMA-PET scans detected metastatic disease in 46% of patients, indicating understaging by conventional imaging in high-risk nonmetastatic hormone-sensitive prostate cancer. The study involved 182 ...

One-third of patients with PSA levels below 0.2 ng/mL after radical prostatectomy have recurrent disease identifiable by PSMA PET. More than one-third of patients with PSA levels less than 0.5 ng/mL ...

One test could have prevented terminal prostate cancer, says patient - Research has shown that the use of the PSA test varies ...

Metastatic prostate cancer continues to decline in incidence, but the proportion of cases being diagnosed in younger men is increasing, according to a study. Researchers analyzed population-based ...

The American Cancer Society estimates that more than 313,780 cases of prostate cancer will be diagnosed in the United States in 2025, resulting in approximately 35,770 deaths. Bone metastasis - a ...

In a recent study published in Scientific Reports, a group of researchers investigated the differences in prostate magnetic resonance imaging (MRI) findings and clinical characteristics between ...